调节性T细胞与原发性肝癌的免疫治疗  

Regulatory T cells and immunotherapy of primary hepatocellular carcinoma

作　　者：沈顺利[1] 梁力建[1] 

机构地区：[1]中山大学附属第一医院肝胆外科,广州510080

出　　处：《中华肝胆外科杂志》2010年第4期314-317,共4页Chinese Journal of Hepatobiliary Surgery

基　　金：广东省自然科学基金（8151008901000161）;国家自然科学基金（30872486）

摘　　要：原发性肝癌的免疫治疗近年来发展迅速，在基础和l临床前期研究中取得了令人鼓舞的治疗成果。但和其它恶性肿瘤类似，肝癌存在着严重的肿瘤免疫微环境抑制，大大影响了肝癌免疫治疗的效果。调节性T细胞（Treg）是一类免疫负性调控细胞，在维持人体自身免疫稳定和抗肿瘤免疫过程中起着重要作用，是形成肿瘤免疫微环境抑制的重要机制之一。有关Treg同肝癌的研究表明，Treg有可能成为肝癌免疫治疗的潜在靶点。Immunotherapy of hepatocellular carcinoma （HCC） develops rapidly in recent years and has yielded encouraging results in both experimental and pre-clinical stud- ies. However, similar to other malignant tumors, there ex ists serious immune suppression in HCC tumor microenvi ronment, which significantly affected the therapeutic effect of HCC immunotherapy. Regulatory T cells （Treg） are a group of immune negative regulation cells. It plays an impor rant role in maintaining the homeostasis of the immune sys tern and is one of the most important mechanisms of immune mieroenvironment suppression. Studies concerning Treg and HCC indicate that Treg might be the potential target for HCC immunotherapy.

关 键 词：原发性肝癌 免疫治疗 调节性T细胞 免疫微环境 

分 类 号：R735.7[医药卫生—肿瘤]